Zoloft (sertraline chloride) is an antidepressant developed and manufactured by Pfizer. The U.S. Food and Drug Administration approved it for sale in the U.S. in 1990. Pfizer originally sold Zoloft in the U.K. under the brand name Lustral, and it took nine years for Americans to gain access to it. Pfizer developed and marketed Zoloft as a safer alternative with fewer side effects and withdrawal symptoms than competitor drugs such as Eli Lilly’s Prozac.
By 2005, Zoloft was the most popularly prescribed antidepressant on the U.S. market, with nearly 30 million prescriptions. In that same year, it was the sixth most prescribed brand-name prescription medication, grossing nearly $ 3.3 billion.
Pfizer lost the Zoloft patent in 2006, but announced that it would manufacture a generic version through its Greenstone division. The drug giant’s authorized generic made $2.6 billion in 2006. Even without patent, doctors wrote 41.5 million prescriptions for Zoloft by 2013.
Other manufacturers of generic sertraline include Roxane, Roerig, Teva Pharmaceuticals, Barr Laboratories, Mylan Laboratories and Dr. Reddy’s Labs.
How Does Zoloft Work?
Zoloft comes from a class of antidepressant drugs known as SSRIs (selective serotonin reuptake inhibitors).
SSRIs control depression and other mental illnesses and have been around since the early 1980s. Today, they are the most prescribed class of antidepressant medication on the U.S. market. They are popular mainly due to the fact that they have fewer side effects than other types of antidepressants. SSRIs work by controlling the brain’s level of serotonin, which is a neurotransmitter thought to affect mood, sleep and learning.
Zoloft primarily treats major depressive disorder (MDD). However, doctors also prescribe it for post-traumatic stress disorder (PTSD), premenstrual dysphoric disorder (PMDD), obsessive-compulsive disorder (OCD), social anxiety disorder and panic disorder. While Zoloft is not indicated for use in children, the FDA approved Zoloft to treat Obsessive-Compulsive Disorder (OCD) in children and adolescents age 6 to 17.
MDD affects nearly 7 percent of the U.S. adult population. If MDD goes untreated, the lifetime risk of suicide is 20 percent.
Diagnosis of MDD comes after some or all of the following symptoms occur for more than two weeks:
- Sad or depressed mood.
- Changes in appetite and sleep.
- Mental and physical agitation.
- Thoughts of suicide.
- Loss of interest in most activities.
- Feeling worthless/guilty/hopeless/helpless.
- Difficulty concentrating.
Off-Label Zoloft Uses
Zoloft also has several off-label uses — uses not approved by the FDA. Because Zoloft works by altering brain chemistry, some doctors may prescribe it to patients with a variety of issues. But, there is no extensive clinical trial data for off-label uses, and the FDA has not reviewed Zoloft for safety or effectiveness for these indications. There are also no official dosages for these uses.
Some off-label uses include:
- Diabetic neuropathy
- Eating disorders
- Hot flashes
- Generalized anxiety disorder
- Personality disorders
- Tourette syndrome
- Premature ejaculation
Zoloft and its generic forms come in both tablet and oral concentrate form. Typical dosage for treating depression is 50 mg once a day. But, the dose varies for other indications. Zoloft has a 24-hour elimination half-life, so changes in dose should not occur in intervals less than one week. As with many psychiatric medications, a patient may develop a tolerance to Zoloft. Doctors may increase the dose in order for the drug to keep working.
- Panic Disorder, Posttraumatic Stress Disorder and Social Anxiety Disorder: Initial dose of 25 mg once daily, increased to 50 mg after one week. Patients not responding to 50 mg may increase the dose up to 200 mg. Patients with Panic Disorder, PTSD or Social Anxiety Disorder generally need several months or longer of sustained medication, but there is no proven dosage data for lifetime maintenance treatment with Zoloft.
- Premenstrual Dysphoric Disorder: Initial dose of 50 mg per day during the menstrual cycle or during the luteal phase — just before the beginning of the period. The dose for PMDD varies from 50 to 150 mg per day. Doctors may be increase the dose during each menstrual cycle. Clinical trials did not test the effectiveness of Zoloft for more than three menstrual cycles.
- Adult Obsessive-Compulsive Disorder: 50 mg once daily. In trials, patients took 50 to 200 mg a day. There is no trial data for efficacy past 52 weeks.
- Pediatric Obsessive-Compulsive Disorder: Children ages 6 to 12 should start with 25 mg once daily and 50 mg in children ages 13 to 17. In clinical trials, patients used doses of 25 mg to 200 mg daily.
Common Side Effects of Zoloft
Most patients tolerate Zoloft well, but it still has side effects that vary in severity. Common side effects of Zoloft are milder than first-generation antidepressants.
Minor side effects of Zoloft that typically decrease after the first or second week of use include:
- Weight loss or gain
- Increased sweating
- Sleepiness or insomnia
- Dry mouth
- Suicidal Thoughts
- Sexual Dysfunction
- Fever (in children)
- Urinary incontinence (in children)
- Aggression (in children)
Some users experience sexual side effects, including problems with orgasm and ejaculatory delay and impotence. These do not typically decrease with use.
Black Box Warning for Suicide
Zoloft causes some younger users of the drug to report being suicidal. The FDA requires Zoloft and all antidepressants to carry a black-box warning about the danger of suicide during the initial stages of treatment, especially in children. Clinical studies have shown that a small number of younger users of antidepressants, including sertraline, become suicidal.
People who stop taking SSRIs may suffer from what doctors call discontinuation syndrome. The symptoms may be most intense the first week and slowly taper off. But, some people may have a longer withdrawal period.
According to Harvard physician Dr. Joseph Glenmullen, author of The Antidepressant Solution, about 60 percent of people who took Zoloft experience withdrawal reactions. Many patients who wish to stop medication often continue to take it or increase their dose because doctors mistake withdrawal symptoms for a depressive relapse, Glenmullen said. The severity of symptoms may be dependent on dose and duration.
Symptoms of discontinuation syndrome include:
- Loss of coordination
- Blurred vision
- Vivid dreams
- Flu-like symptoms
- Crying spells
Zoloft Side Effects in Clinical Trials
Researchers noted more serious side effects during premarket Zoloft clinical trials of over 4,000 patients. These side effects were more rare, but worth noting in studies. According to researchers, while these events occurred while receiving Zoloft, there is no definite proof that Zoloft caused these adverse events.
Reported side effects include:
- Urinary problems
- Flu-like symptoms
- Menstrual disorder
- Breast pain
- Ear and eye pain
- Muscle cramps
- Weight increase
- Back pain
- Weight loss
Zoloft and Autism
One of the most recent side effects linked to the use of Zoloft and other SSRIs during pregnancy is autism spectrum disorder, also referred to as ASD. ASD is a developmental disorder that impairs a person’s ability to communicate and interact.
“Our study has established that taking antidepressants during the second or third trimester of pregnancy almost doubles the risk that the child will be diagnosed with autism by age 7, especially if the mother takes selective serotonin reuptake inhibitors, often known by its acronym SSRIs.”
– Professor Anick Bérard, University of Montreal
A 2015 study published in JAMA Pediatrics showed that Zoloft and other SSRIs were associated with a 200 percent increased risk of having a child born with autism while antidepressants in general had an 87 percent overall increased risk.
Boys are more likely to be diagnosed with autism than girls, and older mothers are more likely to have autistic children.
A Johns Hopkins study from April 2014 published in Pediatrics, showed boys born to mothers who used SSRIs during pregnancy were three times more likely to be autistic.
Zoloft and Pregnancy
Women who are pregnant or considering becoming pregnant should consult their doctors prior to taking Zoloft or continuing treatment. Studies show Zoloft may cause serious birth defects when taken during pregnancy, as well as withdrawal symptoms in the baby following birth.
Women who take Zoloft during the third trimester of pregnancy gave birth to babies who required prolonged hospitalization, respiratory support and tube feeding, according to premarketing studies.
While the FDA no longer uses pregnancy categories to determine a drug’s safety during pregnancy, it previously categorized Zoloft a category C drug. This means that animal studies have shown some harm to the fetus, but there have been no adequate studies in humans.
Research shows, however, that babies born to mothers who have taken Zoloft or another SSRI after the 20th week of pregnancy are more likely to suffer from persistent pulmonary hypertension of the newborn (PPHN), which is fatal in 10 percent of cases. In addition, one study showed that women taking sertraline had twice the risk of having a baby born with a heart defect.
Using SSRIs while pregnant — or even up to a month before conception — can lead to a fatal birth defect called anencephaly, in which a large portion of the brain and skull never develops. In addition, babies are more likely to suffer from facial malformations such as cleft lip and cleft palate if a mother took an SSRI during pregnancy. Taking an antidepressant while pregnant can also put babies at risk for withdrawal symptoms. The side effects can be serious, but the risk of a birth defect occurring is relatively low.
Patients with kidney disease or liver disease, or who suffer from seizures, mania or suicidal thoughts, should speak to their doctor before using Zoloft. Patients who are allergic to ingredients in Zoloft should not take it. In addition, Zoloft can cause interactions with other drugs or supplements.
- Taking Zoloft NSAID pain relievers or blood thinners such as warfarin (Coumadin) may increase the risk of stomach bleeding.
- Zoloft should not be taken with alcohol
- Do not take St. John’s Wort with Zoloft
- Lithium combined with SSRIs like Zoloft can cause serotonin syndrome
- MAOIs or tryptamine-based drugs for headaches combined with Zoloft may cause serotonin syndrome
Serotonin syndrome is a serious condition that can be recognized by the following symptoms:
- Nausea or vomiting
- Loss of coordination
- Rapid heartbeat
Doctors typically will decrease the dosage of an SSRI before stopping treatment altogether. Otherwise, withdrawal symptoms can occur, including irritability, nausea, dizziness, vomiting, nightmares and headache.
- "A History of SSRIs." Retrieved June 10, 2012, from http://seroxatsecrets.files.wordpress.com/2007/03/a-history-of-ssris.pdf
- Nauert, R. (2014, April 16) 1st Trimester Antidepressant Use Tied to Autism Risk. Retrieved from http://psychcentral.com/news/2014/04/16/1st-trimester-antidepressant-use-tied-to-autism-risk/68613.html
- University of Montreal. (2015, December 14). Taking antidepressants during pregnancy increases risk of autism by 87 percent. [Press Release]. Retrieved from http://www.sciencedaily.com/releases/2015/12/151214130227.htm
- Butler, J and Leonard B. E. (1998 October). "The Platelet Serotonergic System in Depression and Following Sertraline Treatment." Vol 3.4. International Clinical Psychopharmacology. Retrieved from http://journals.lww.com/intclinpsychopharm/Abstract/1988/10000/The_Platelet_Serotonergic_System_in_Depression_and.5.aspx
- College of Psychiatric and Neurological Pharmacists. (2007 May)"Zoloft Fact Sheet." National Alliance of Mental Illness. Retrieved from http://www.namihelps.org/assets/PDFs/fact-sheets/Medications/Zoloft.pdf
- "FDA Approves First Generic Sertraline." (2006 June 30). United States Food and Drug Administration.
- Flament, MF, Lane RM, Ying, Z. (1999 September). "Predictors of an Acute Antidepressant Response to Fluoxetine and Sertraline." Vol 14.5. International Clinical Psychopharmacol. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/10529069
- Harris, Gardiner. (2009 September 2). "Pfizer Pays $2.3 Billion to Settle Marketing Case." The New York Times. Retrieved from http://www.nytimes.com/2009/09/03/business/03health.html?_r=2
- Alarcon, Renato D. (2004). "Antidepressants: Past, Present and Future."
- Hostetter, Amy, James C. Ritchie and Zachary N. Stowe. (2000 June 7). "Amniotic Fluid and Umbilical Cord Blood Concentrations of Antidepressants in Three Women." Vol. 48.10. Biological Psychiatry. Retrieved from http://www.biologicalpsychiatryjournal.com/article/S0006-3223%2800%2900958-6/abstract
- Kotz, Deborah. (2007 June 27). "Some Antidepressants Birth Defect Risks." U. S. News and World Report.
- Louik, Carol, Angela E. Lin, M.D., Martha M. Werler, Sc. D., Sonia Hernandez-Diaz, M. D., and Allen A. Mitchell, M.D.. (2007 June 28). "First-Trimester Use of Selective Serotonin-Reuptake Inhibitors and the Risk of Birth Defects." New England Journal of Medicine. Retrieved from http://www.nejm.org/doi/full/10.1056/NEJMoa067407
- Pfizer. "Zoloft" Medication Guide. Retrieved June 10, 2010 from http://labeling.pfizer.com/ShowLabeling.aspx?id=517
- Quallich, George J. (2005 March 18). "Development of the Commercial Process for Zoloft/sertraline." Vol 17.1. Chirality. Retrieved from http://onlinelibrary.wiley.com/doi/10.1002/chir.20113/abstract
- Wagner, Karen Dineen, MD, PhD; Paul Ambrosini, MD; Moira Rynn, MD; Christopher Wohlberg, MD, PhD; Ruoyong Yang, PhD; Michael S. Greenbaum, MD; Ann Childress, MD; Craig Donnelly, MD; Deborah Deas, MD; (2003 August 27). "Efficacy of Sertraline in the Treatment of Children and Adolescents with Major Depressive Disorder." Vol 290.8. Journal of the American Medical Association. Retrieved from http://jama.jamanetwork.com/article.aspx?articleid=197174
- Weller, Ian V. D, M.D.(2004 December) "Report of the CSM Expert Working Group on the Safety of Selective Serotonin Reuptake Inhibitor Antidepressants." Retrieved from http://www.mhra.gov.uk/home/groups/pl-p/documents/drugsafetymessage/con019472.pdf
- "Before the United States Judicial Panel on Multidistrict Litigation." (2012 January 18) Case 2342. Retrieved from http://impaneled.files.wordpress.com/2012/02/zololft-defs-init-mot.pdf